版本:
中国

BRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy

May 16 Adaptimmune Therapeutics Plc:

* Adaptimmune announces initiation of study to evaluate spear t-cell therapy targeting mage-a4 in multiple solid tumors

* Adaptimmune Therapeutics Plc - phase i, open label, dose escalation study to evaluate mage-a4 will enroll up to 32 patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐